CORBUS PHARMACEUTICALS HOLDINGS

Corbus Pharmaceuticals Holdings is a clinical stage pharmaceutical company focused on the development and commercialization of therapeutics to treat chronic and serious inflammatory and fibrotic diseases. The company's product, lenabasum, is a synthetic, oral, cannabinoid (CB2 agonist) designed to resolve chronic inflammation and halt fibrotic processes. The company is developing lenabasum to treat systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. The company's pipeline also includes CRB-4001, a peripherally-restricted, CB1 inverse agonist designed to treat organ specific fibrotic liver diseases, such as nonalcoholic steatohepatitis.
  • TickerCRBP
  • ISINUS21833P1030
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

CORBUS PHARMS.HOLDINGS sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CORBUS PHARMS.HOLDINGS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date December 29, 2020, the closing price was USD 1.26 and its target price was estimated at USD 0.24.

MarketLine Department

Ampio Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Ampio Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Ampio Pharmaceuticals, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its compet...

Jonathan Moreland

InsiderInsights Daily Ratings Report: March 15, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland

InsiderInsights Daily Ratings Report: March 14, 2019

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

CORBUS PHARMS.HOLDINGS sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CORBUS PHARMS.HOLDINGS (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 3 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date December 29, 2020, the closing price was USD 1.26 and its target price was estimated at USD 0.24.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch